Further characterization of PRL3 expression in embryonal and mesenchymal tumors is needed, along with wider clinical experience with use of PRL3-zumab in children, possibly in the context of basket trials for pediatric cancers. This evidence concerns the gene PTP4A3 and mesenchymal cell neoplasm.